Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions
Nanoparticle contrast agents for MRI may aid in identifying atherosclerotic lesions that give rise to ischemic events by means of penetration and retention in the plaque. These imaging agents may provide valuable information regarding plaque characteristics which can help determine the risk of plaqu...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2008-01-01
|
Series: | Clinical Medicine Insights: Cardiology |
Online Access: | https://doi.org/10.4137/CMC.S642 |
id |
doaj-05f880d4ce9f4780a6d57a556c42008e |
---|---|
record_format |
Article |
spelling |
doaj-05f880d4ce9f4780a6d57a556c42008e2020-11-25T03:28:14ZengSAGE PublishingClinical Medicine Insights: Cardiology1179-54682008-01-01210.4137/CMC.S642Nanoparticles as Contrast Agents for MRI of Atherosclerotic LesionsJuan Carlos Frías0Michael Joseph Lipinski1María Teresa Albelda2Borja Ibáñez3Conxa Soriano4Enrique García-España5Luis Jesús Jiménez-Borreguero6Juan José Badimon7Instituto de Ciencia Molecular, University of Valencia, Valencia, Spain.Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA, U.S.A.Instituto de Ciencia Molecular, University of Valencia, Valencia, Spain.The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY, U.S.A.Instituto de Ciencia Molecular, University of Valencia, Valencia, Spain.Instituto de Ciencia Molecular, University of Valencia, Valencia, Spain.Departamento de Cardiología, Hospital Universitario de La Princesa, Madrid, Spain.The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY, U.S.A.Nanoparticle contrast agents for MRI may aid in identifying atherosclerotic lesions that give rise to ischemic events by means of penetration and retention in the plaque. These imaging agents may provide valuable information regarding plaque characteristics which can help determine the risk of plaque rupture. By increasing molecular flexibility or adding a means of specifically targeting ligands via antibody or peptide, nanoparticles can enhance certain regions of the atherosclerotic plaque. The development of single contrast agents detectable with multiple imaging modalities may further improve our ability to detect and characterize atherosclerosis in clinical and preclinical applications. These exciting developments may help in the realization of MRI as a powerful tool in the prevention of cardiovascular morbidity and mortality.https://doi.org/10.4137/CMC.S642 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Juan Carlos Frías Michael Joseph Lipinski María Teresa Albelda Borja Ibáñez Conxa Soriano Enrique García-España Luis Jesús Jiménez-Borreguero Juan José Badimon |
spellingShingle |
Juan Carlos Frías Michael Joseph Lipinski María Teresa Albelda Borja Ibáñez Conxa Soriano Enrique García-España Luis Jesús Jiménez-Borreguero Juan José Badimon Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions Clinical Medicine Insights: Cardiology |
author_facet |
Juan Carlos Frías Michael Joseph Lipinski María Teresa Albelda Borja Ibáñez Conxa Soriano Enrique García-España Luis Jesús Jiménez-Borreguero Juan José Badimon |
author_sort |
Juan Carlos Frías |
title |
Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions |
title_short |
Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions |
title_full |
Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions |
title_fullStr |
Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions |
title_full_unstemmed |
Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions |
title_sort |
nanoparticles as contrast agents for mri of atherosclerotic lesions |
publisher |
SAGE Publishing |
series |
Clinical Medicine Insights: Cardiology |
issn |
1179-5468 |
publishDate |
2008-01-01 |
description |
Nanoparticle contrast agents for MRI may aid in identifying atherosclerotic lesions that give rise to ischemic events by means of penetration and retention in the plaque. These imaging agents may provide valuable information regarding plaque characteristics which can help determine the risk of plaque rupture. By increasing molecular flexibility or adding a means of specifically targeting ligands via antibody or peptide, nanoparticles can enhance certain regions of the atherosclerotic plaque. The development of single contrast agents detectable with multiple imaging modalities may further improve our ability to detect and characterize atherosclerosis in clinical and preclinical applications. These exciting developments may help in the realization of MRI as a powerful tool in the prevention of cardiovascular morbidity and mortality. |
url |
https://doi.org/10.4137/CMC.S642 |
work_keys_str_mv |
AT juancarlosfrias nanoparticlesascontrastagentsformriofatheroscleroticlesions AT michaeljosephlipinski nanoparticlesascontrastagentsformriofatheroscleroticlesions AT mariateresaalbelda nanoparticlesascontrastagentsformriofatheroscleroticlesions AT borjaibanez nanoparticlesascontrastagentsformriofatheroscleroticlesions AT conxasoriano nanoparticlesascontrastagentsformriofatheroscleroticlesions AT enriquegarciaespana nanoparticlesascontrastagentsformriofatheroscleroticlesions AT luisjesusjimenezborreguero nanoparticlesascontrastagentsformriofatheroscleroticlesions AT juanjosebadimon nanoparticlesascontrastagentsformriofatheroscleroticlesions |
_version_ |
1724585514640605184 |